📊$TSLA &$MRNA.US — Latest Analysis
TSLA: Tesla closed around $362.86 on Aug. 21. The stock is showing a short-term recovery, but competition, high valuation and heavy investment in autonomy remain key risks.
MRNA: Moderna remains extremely volatile. After a huge rally on positive Phase 3 melanoma-cancer-vaccine results, shares pulled back sharply. The long-term story has improved, but the recent move makes volatility and profit-taking major risks.
Bottom line: TSLA looks like a cautious recovery play, while MRNA is a high-risk/high-volatility biotech momentum trade.
#TSLA #MRNA #AnthropicIPOCouldTopSpaceXRecordReportsSay #NvidiaAIServerPricesRiseOver15% #BSTREndsCantorSPACGoPublicPlan
TSLA: Tesla closed around $362.86 on Aug. 21. The stock is showing a short-term recovery, but competition, high valuation and heavy investment in autonomy remain key risks.
MRNA: Moderna remains extremely volatile. After a huge rally on positive Phase 3 melanoma-cancer-vaccine results, shares pulled back sharply. The long-term story has improved, but the recent move makes volatility and profit-taking major risks.
Bottom line: TSLA looks like a cautious recovery play, while MRNA is a high-risk/high-volatility biotech momentum trade.
#TSLA #MRNA #AnthropicIPOCouldTopSpaceXRecordReportsSay #NvidiaAIServerPricesRiseOver15% #BSTREndsCantorSPACGoPublicPlan
